| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cellular Biology |
From BHF Laboratories and Department of Medicine, University College London, London, UK.
Correspondence to Andrew Tinker, BHF Laboratories and Department of Medicine, University College London, 5 University St, London WC1E 6JJ, UK. E-mail a.tinker{at}ucl.ac.uk
| Abstract |
|---|
|
|
|---|
Key Words: ATP-sensitive K+ channels ion channel regulation anionic phospholipids protein kinase C
| Introduction |
|---|
|
|
|---|
KATP is an octameric protein complex composed of pore-forming subunits (Kir6.1 and Kir6.2), a member of the inwardly rectifying family of K+ channels (Kir), and the sulfonylurea receptor subunit, a member of the ATP-binding cassette family of proteins (SUR1, SUR2A, and SUR2B). The assembly of a particular pore-forming subunit with a particular SUR generates currents with a characteristic single-channel conductance, nucleotide regulation, and pharmacology.79 It has been proposed that SUR2B/Kir6.1 is the molecular counterpart of the vascular smooth muscle KATP current, with properties akin to that of the nucleotide diphosphatesensitive K+ (KNDP) current.10,11 SUR2B/Kir6.2 has more classic properties and is proposed to constitute the KATP current in nonvascular smooth muscles.12 It is not clear yet whether this broad generalization is correct, but studies with Kir6.1- and SUR2-knockout mice and our own work involving a primary pulmonary artery smooth muscle cell line are consistent with the native vascular channel being composed of SUR2B/Kir6.1.1315 In the present study, we examine the regulation of the cloned equivalents of the vascular KATP channel (SUR2B/Kir6.1 and SUR2B/Kir6.2) by anionic phospholipids and PKC.
| Materials and Methods |
|---|
|
|
|---|
(PH-CFP construct) was kindly provided by Dr Tobias Meyer (Stanford University Medical School, Stanford, Calif). Polymerase chain reaction fragments corresponding to the C-termini of rat Kir6.1 (amino acids 179 to 424) and mouse Kir6.2 (amino acids 189 to 391) were subcloned into the pMal-c2x vector (New England Biolabs).
Production and Purification of MBP Fusion Proteins
Fusion protein vectors were transformed into BL21(DE3) Escherichia coli. Fusion protein expression was induced according to the manufacturers instructions, except induction occurred at 20°C overnight. Cells were harvested by centrifugation, and the cell pellet was washed with PBS/5 mmol/L EDTA (column buffer) and resuspended in column buffer containing protease inhibitors (Roche complete protease inhibitor cocktail, EDTA free) before freezing. The cell suspension was rapidly thawed at 37°C and sonicated on ice, and insoluble material was removed by centrifugation at 10 000g for 30 minutes at 4°C. The supernatant was applied to a column containing a 2-mL bed volume amylose-binding resin and washed with 12 column volumes before elution with column buffer containing 10 mmol/L maltose. Protein-containing fractions were pooled and dialyzed against the column buffer. The protein concentration of the purified fusion proteins was measured, and purity was assessed by SDS-PAGE, followed by Coomassie blue staining. After purification, the C-terminus of Kir6.2 (maltose-binding protein [MBP]-Kir6.2C) was judged to be
90% pure, and the C-terminus of Kir6.1 (MBP-Kir6.1C) was judged to be
80% pure, with a lower molecular weight species consistently present.
Lipid-Binding Experiments
Nitrocellulose strips spotted with lipids (PIP strips, Molecular Probes Inc) were blocked for 1 hour in a blocking solution composed of 50 mmol/L Tris-HCl, 150 mmol/L NaCl, 5 mmol/L KCl, pH 7.4, and 0.1% (vol/vol) Tween containing 3% (wt/vol) BSA with low fatty acid content (<0.02%) at room temperature. After the blocking, the strips were incubated overnight at 4°C with a 0.5 µg/mL solution of the appropriate MBP fusion protein in blocking solution. Strips were then processed as for Western blotting using a rabbit primary antibody to the MBP fusion protein. Strips of nitrocellulose were spotted with L-
-PtdIns(4,5)P2 in a total volume of 2 µL for each spot from a 500 µmol/L stock in chloroform/methanol/H2O (50:50:15).
Phosphorylation Assay
The fusion proteins bound to the amylose resin were washed with 1 mL of 5x HEPES buffer (50 mmol/L HEPES, pH 7.4, 1 mmol/L EDTA, 10% glycerol, 5 mmol/L sodium pyrophosphate, 50 mmol/L sodium fluoride, 1 mmol/L dithiothreitol, and protease inhibitors). Added to 10 µg protein was 20 ng catalytically active PKC (obtained from Calbiochem), 6 µL of 5x buffer (50 mmol/L HEPES, 1 mmol/L ATP, and 50 mmol/L MgCl2), 10 µL HEPES buffer, 13 µL of 50 mmol/L HEPES, 1.5% Triton, and 1 µL 32P-
-ATP (omitted in the case of lipid-binding experiments). The sample was incubated at 37°C for 2 hours and then washed five times with 1 mL HEPES buffer. The protein was eluted, run on an SDS-PAGE gel, dried, and subjected to autoradiography. Gel quantification was performed by using Scion image (Scion Corp).
Cell Culture and Transfection
The culture and transfection of HEK293 cells and the use of stable cell lines expressing SUR2B/Kir6.1 and SUR2B/Kir6.2 were as previously described.17
Confocal Microscopy
HEK293 cells were imaged at room temperature (20°C) using a Bio-Rad Radiance 2000 laser scanning confocal microscope. Samples were excited using a 458-nm laser line, and images were obtained by using a 500-nm-long band-pass filter. Images were processed and quantified using LaserPix software (Bio-Rad). A commercially available Krebs-Ringer buffer with glucose (K4002, Sigma) was used for perfusion; this was supplemented with 2.6 mmol/L Ca2+ and used according to the manufacturers instructions.
Electrophysiology
Whole-cell and inside-out patch-clamp recordings were performed as previously described.17,18 Capacitance transients and series resistance in whole-cell recordings were compensated electronically by using amplifier circuitry. Pipette (whole-cell) and bath (inside-out) solutions contained (mmol/L) KCl 107, MgCl2 1.2, CaCl2 1, EGTA 10, and HEPES 5 (KOH to pH 7.2,
140 mmol/L K+). In whole-cell studies, bath solutions contained (mmol/L) KCl 140, CaCl2 2.6, MgCl2 1.2, and HEPES 5 (pH 7.4); in perforated-patch experiments, solutions contained (mmol/L) NaCl 140, KCl 5, MgCl2 1.2, CaCl2 2.6, HEPES 5, and D-glucose 8 (pH 7.4). Nucleotide supplementation of the pipette/bath solution is indicated in the legends. The pH of the solution was checked after nucleotide supplementation and adjusted if needed. Whole-cell experiments were dialyzed for at least 5 minutes before the recordings. For perforated-patch experiments, a stock solution of 100 mg/mL amphotericin B in dimethyl sulfoxide was prepared and diluted in a standard pipette solution to give a final concentration of 200 µg/mL amphotericin B. A stable access resistance was obtained after 10 to 15 minutes (
10 M
). Generally, agents were applied to the bath by using a gravity-driven system or were applied locally to a cell via a plastic pipette (MSC-200, IntraCel).
Materials
PtdIns(4,5)P2 was obtained from Calbiochem, and fresh solutions were made each day. Liposomes were prepared by sonication of the bath solution for 30 minutes. In the electrophysiological experiments, we used the natural derivative with the arachidonyl and stearyl side chains. For the binding assays, we used the synthetic dipalmitoyl-C16 derivative. It is worth noting that the commercially available strips used in Figure 7A contain these derivatives. The PtdIns(4,5)P2 antibody was obtained from Assay Design Inc. The translocation-inhibiting peptide for PKC
and the control were obtained from Calbiochem.
|
Statistical Analysis
Statistical analysis was carried out by using one-way ANOVA or a paired Student t test as appropriate. Statistical significance is indicated in the figures (P<0.05, P<0.01, and P<0.001). Data are presented as mean±SEM. Current density and open probability (NPo) are presented normalized to control, where appropriate, to enable the assessment of the relative magnitude of the responses. The mean raw measurements are given in the text of the figure legends, and the statistical analyses shown were performed on such data.
| Results |
|---|
|
|
|---|
|
|
We next sought to confirm this by activating PKC in a receptor-independent fashion using phorbol esters. Membrane currents were studied in the whole-cell configuration, and Figure 3 shows that phorbol 12-myristate 13-acetate (PMA) and phorbol 12,13-dibutyrate (PdBu) were able to inhibit SUR2B/Kir6.1 currents, whereas they were ineffective when applied to a stable line expressing SUR2B/Kir6.2. The inactive phorbol ester 4
-phorbol didecanoate was ineffective at modulating currents when it was applied to the cell line expressing SUR2B/Kir6.1 (Figure 3). Our pipette solution has a calculated free Ca2+ concentration of 20 nmol/L, implicating a Ca2+-independent isoform of PKC. Thus, we used a PKC
translocation inhibition peptide, and this abrogated the inhibition (Figure 3). In addition, phorbol esters were ineffective at modulating Kir6.2 currents when membrane currents were studied with the perforated-patch technique (not shown).
|
We next examined the role of the substrates of PLC and investigated the potential differences in regulation by anionic phospholipids in inside-out patches expressing SUR2B/Kir6.2 and SUR2B/Kir6.1. One of the indirect hallmarks of such regulation is channel rundown in ATP-free solutions. Figure 4 shows that SUR2B/Kir6.2 channel activity runs down in ATP-free solutions and that this activity is restored by the application of 10 µmol/L PtdIns(4,5)P2. In contrast, SUR2B/Kir6.1-containing complexes do not run down when they are examined under comparable conditions, and the application of PtdIns(4,5)P2 does not increase single-channel NPo. SUR2B/Kir6.2 currents ran down in an equivalent fashion in the presence of UDP and pinacidil (mean NPo at the start was 0.3337±0.0837, which significantly runs down to 0.0275±0.0269 after 20 minutes; n=6). There are two potential explanations for the inability to demonstrate rundown and the effects of PtdIns(4,5)P2 on SUR2B/Kir6.1 activity. One is that the activity of the channel complex is independent of anionic phospholipids. Alternatively, Kir6.1 channel activity is dependent on anionic phospholipids, but the interaction is stronger, and the affinity is much higher than that for Kir6.2. We designed a further set of experiments to test this. Poly-L-lysine is able to antagonize the actions of PtdIns(4,5)P2, and heparin is able to reverse this effect. In inside-out patches, poly-L-lysine was able to inhibit both SUR2B/Kir6.2 and SUR2B/Kir6.1. Channel activity could be recovered by the subsequent application of heparin and PtdIns(4,5)P2 (Figure 5). Finally, we examined the consequences of including an anti-PtdIns(4,5)P2 antibody in the recording pipette in the whole-cell configuration. It is thought that the antibody binds to the negatively charged phosphate groups, shielding interaction with basic residues on the channel protein. Dialysis with a pipette solution containing 1 mmol/L ATP led initially to an increase in current, which peaked within 5 minutes and then relaxed to a steady state at
10 minutes (this relaxation was more pronounced after inclusion of the antibody). We measured both these parameters in control conditions and after the inclusion of the antibody in the pipette solution. In the latter condition, the antibody significantly reduced the current density in the stable cell line expressing SUR2B/Kir6.2 (Figure 6). In contrast, inclusion of the PtdIns(4,5)P2 antibody in the pipette solution and dialysis for 5 minutes in whole-cell recordings from SUR2B/Kir6.1 did not change the magnitude of the pinacidil-stimulated currents (Figure 6).
|
|
|
A potential explanation for the observed functional phenomena is that the affinity of Kir6.1 for anionic phospholipids is much higher than that for Kir6.2. Thus, we sought more direct biochemical evidence for this. A number of studies have revealed that the major determinants for anionic phospholipid binding are located in the C-terminus of the channel subunit.2,2123 Thus, we generated and purified soluble bacterial fusion proteins of these domains linked to the MBP and also the control protein MBP. We used these in overlay binding assays against membranes spotted with a series of anionic phospholipids (100 pmol; see Materials and Methods). We found that MBP-Kir6.1C, but not MBP-Kir6.2C or MBP, bound significantly to these membranes (Figures 7A and 7B). Intriguingly, PtdIns 4-monophosphate [PtdIns(4)P], PtdIns 5-monophosphate [PtdIns(5)P], and PtdIns 3,4-diphosphate [PtdIns(3,4)P2] showed particularly strong (and statistically significant) binding, but PtdIns(4,5)P2 did not. There was also a trend for a number of others to bind above background levels to MBP-Kir6.1C, but this was not statistically significant. Figure 7C shows that it was possible to detect weak but statistically significant binding of MBP-Kir6.1, but not MBP-Kir6.2 or MBP, to nitrocellulose membranes spotted with PtdIns(4,5)P2 at higher concentrations.
Finally, we examined whether the C-terminus of Kir6.1 was a substrate for phosphorylation by PKC and whether this modulated the sensitivity to anionic phospholipids. We performed in vitro phosphorylation assays that showed that MBP-Kir6.1C, but not MBP, was phosphorylated by PKC (Figure 8A). However, phosphorylated protein was still able to bind PtdIns(4)P and PtdIns(5)P at a level equivalent to that for nonphosphorylated protein (Figure 8B).
|
| Discussion |
|---|
|
|
|---|
The central question that we have attempted to address in the present study is whether the substrate or downstream products of PLCß are important for signaling to KATP channels. We have studied the likely cloned equivalents of the smooth muscle channels, namely, SUR2B/Kir6.1 and SUR2B/Kir6.2, because of the background of prominent hormonal regulation in native tissues. Our data reveal novel differences between Kir6.1 and Kir6.2 and show how phospholipid affinity integrates with protein kinase regulation for this important channel family. SUR2B/Kir6.1 is regulated by PKC, and depletion of PtdIns(4,5)P2 or related anionic phospholipids does not have a major role in receptor-mediated regulation. However, we show that the provision of some PtdIns(4,5)P2 or related anionic phospholipids is necessary for SUR2B/Kir6.1 channel activity. In other words, anionic phospholipids are playing a role that is analogous to an enzymatic cofactor. In addition, we have implicated PKC
as the major PKC isoform responsible for regulation, and this is consistent with studies in vascular smooth muscle.29 It is also interesting to note that the magnitude of inhibition is greater via M3 than with phorbol esters, suggesting that another pathway, such as PKA, may be involved.29
In contrast, SUR2B/Kir6.2 is regulated by PtdIns(4,5)P2 but not by PKC. The regulation of Kir6.2-containing channel complexes seems especially controversial. Our data and those of others show a PKC-independent inhibition of cloned KATP channel activity.35 This has recently been extended to inhibition via the
1-adrenergic receptor in native ventricular myocytes.30 In contrast, other investigators have demonstrated a PKC-dependent activation of the native cardiac KATP channel and its cloned equivalents, SUR2A/Kir6.2 and SUR2B/Kir6.2.31,32 Such pathways are potentially important, inasmuch as the sarcolemmal KATP channel is once again assuming importance in cellular protective phenomena.26,33 The picture is further complicated by the failure to observe any changes in PtdIns(4,5)P2 concentration using biochemical methods in cardiac atrial and ventricular cells after Gq/11 receptor stimulation.34
Emerging from a number of laboratories is a consensus that anionic phospholipids are an important factor necessary for the activity of Kirs and other transporters and channels.1 In the case of Kirs, it seems there is a direct interaction between the phospholipid and basic residues present on the C-terminus of the channel1,21 and that this potentially can be regulated by protein kinases.35 A key point is whether under physiological conditions in native tissues, receptor activation leads to sufficiently large changes in PtdIns(4,5)P2 concentration relative to the EC50 for channel activation such that activity is modulated. It is apparent for the inwardly rectifying family of K+ channels that the affinity and kinetics of this interaction can vary. For example, Kir2.1 interacts avidly with PtdIns(4,5)P2, whereas the interaction with Kir3.1/3.4 and Kir2.3 is weaker.36 Thus, we propose that the affinity for PtdIns(4,5)P2 or related anionic phospholipids is weaker for Kir6.2 than for Kir6.1 and that the EC50 for channel activation is numerically higher and within the range for physiological modulation. In contrast, Kir6.1 has much higher affinity, and the variations in PtdIns(4,5)P2 or related anionic phospholipids occur at concentrations that result in saturating activity and thus do not result in changes in activity on receptor activation, even with receptor overexpression. Channel behavior is modulated by phosphorylation by PKC and protein kinase A, and it is also evident that PKC does not seem to act by modulating the anionic phospholipid sensitivity, as has been recently seen with other inward rectifiers.35 Furthermore, there is evidence of a direct competition between nucleotides and anionic phospholipids over a short C-terminal domain in KATP channels.23,37 Our data would explain why Kir6.1-containing channel complexes are less sensitive to inhibition by ATP and thus show basal activity in smooth muscle.10 In addition, there are some interesting, more speculative features with these data. It is clear that the Kir6.1 C-terminus binds with higher affinity to the phosphoinositol species, such as PtdIns(4)P than any others, including PtdIns(4,5)P2, and may explain why the PtdIns(4,5)P2 antibody did not affect whole-cell currents and why PtdIns(4,5)P2 reactivated SUR2B/Kir6.2 better in the presence of poly-L-lysine. Studies to date show that the whole complex of Kir6.2 can bind to a range of inositol phospholipids37 and that inward rectifiers have distinct phosphoinositide preferences at the functional level.36
Thus, our data show evidence of distinct inhibitory mechanisms, accounting for regulation of the highly homologous Kir6.1 and Kir6.2. The elucidation of residues and domains underlying these phenomena will contribute significantly to their understanding, and we are currently pursuing such studies.
| Acknowledgments |
|---|
| Footnotes |
|---|
Original received February 20, 2003; resubmission received July 7, 2003; revised resubmission received September 2, 2003; accepted September 3, 2003.
| References |
|---|
|
|
|---|
2. Fan Z, Makielski JC. Anionic phospholipids activate ATP-sensitive potassium channels. J Biol Chem. 1997; 272: 53885395.
3. Baukrowitz T, Schulte U, Oliver D, Herlitze S, Krauter T, Tucker SJ, Ruppersberg JP, Fakler B. PIP2 and PIP as determinants for ATP inhibition of KATP channels. Science. 1998; 282: 11411144.
4. Shyng S, Nichols CG. Membrane phospholipid control of nucleotide sensitivity of KATP channels. Science. 1998; 282: 11381141.
5. Xie L-H, Horie M, Takano M. Phospholipase C-linked receptors regulate the ATP-sensitive potassium channel by means of phosphatidylinositol 4,5-bisphosphate metabolism. Proc Natl Acad Sci U S A. 1999; 96: 1529215297.
6. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev. 1997; 77: 11651232.
7. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol. 1999; 61: 337362.[CrossRef][Medline] [Order article via Infotrieve]
8. Babenko AP, AguilarBryan L, Bryan J. A view of SUR/KIR6.X, KATP channels. Annu Rev Physiol. 1998; 60: 667687.[CrossRef][Medline] [Order article via Infotrieve]
9. Tucker SJ, Ashcroft FM. A touching case of channel regulation: the ATP-sensitive K+ channel. Curr Opin Neurobiol. 1998; 8: 316320.[CrossRef][Medline] [Order article via Infotrieve]
10. Yamada M, Isomoto S, Matsumoto S, Kondo C, Shindo T, Horio Y, Kurachi Y. Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channel. J Physiol (Lond). 1997; 499: 715720.
11. Beech DJ, Zhang H, Nakao K, Bolton TB. K channel activation by nucleotide diphosphates and its inhibition by glibenclamide in vascular smooth muscle cells. Br J Pharmacol. 1993; 110: 573582.[Medline] [Order article via Infotrieve]
12. Isomoto S, Kondo C, Yamada M, Matsumoto S, Higashiguchi O, Horio Y, Matsuzawa Y, Kurachi Y. A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel. J Biol Chem. 1996; 271: 2432124324.
13. Cui Y, Tran S, Tinker A, Clapp LH. The molecular composition of KATP channels in human pulmonary artery smooth muscle cells and their modulation by growth. Am J Respir Cell Mol Biol. 2002; 26: 135143.
14. Miki T, Suzuki M, Shibasaki T, Uemura H, Sato T, Yamaguchi K, Koseki H, Iwanaga T, Nakaya H, Seino S. Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1. Nat Med. 2002; 8: 466472.[CrossRef][Medline] [Order article via Infotrieve]
15. Chutkow WA, Pu J, Wheeler MT, Wada T, Makielski JC, Burant CF, McNally EM. Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 KATP channels. J Clin Invest. 2002; 110: 203208.[CrossRef][Medline] [Order article via Infotrieve]
16. Leaney JL, Dekker LV, Tinker A. Regulation of a G-protein gated inwardly rectifying potassium channel by a Ca2+-independent protein kinase C. J Physiol (Lond). 2001; 534: 367379.
17. Cui Y, Giblin JP, Clapp LH, Tinker A. A mechanism for ATP-sensitive potassium channel diversity: functional coassembly of two pore forming subunits. Proc Natl Acad Sci U S A. 2001; 98: 729734.
18. Giblin JP, Quinn K, Tinker A. The cytoplasmic C-terminus of the sulfonylurea receptor is important for KATP channel function but is not key for complex assembly or trafficking. Eur J Biochem. 2002; 269: 53035313.[Medline] [Order article via Infotrieve]
19. Botelho RJ, Teruel M, Dierckman R, Anderson R, Wells A, York JD, Meyer T, Grinstein S. Localized biphasic changes in phosphatidylinositol-4,5-bisphosphate at sites of phagocytosis. J Cell Biol. 2000; 151: 13531368.
20. Okubo Y, Kakizawa S, Hirose K, Iino M. Visualization of IP3 dynamics reveals a novel AMPA receptor-triggered IP3 production pathway mediated by voltage-dependent Ca2+ influx in Purkinje cells. Neuron. 2001; 32: 113122.[CrossRef][Medline] [Order article via Infotrieve]
21. Huang CL, Feng SY, Hilgemann DW. Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by G ß
. Nature. 1998; 391: 803806.[CrossRef][Medline]
[Order article via Infotrieve]
22. Shyng SL, Cukras CA, Harwood J, Nichols CG. Structural determinants of PIP2 regulation of inward rectifier KATP channels. J Gen Physiol. 2000; 116: 599608.
23. Dong K, Tang L, MacGregor GG, Hebert SC. Localization of the ATP/phosphatidylinositol 4,5 diphosphate-binding site to a 39-amino acid region of the carboxyl terminus of the ATP-regulated K+ channel Kir1.1. J Biol Chem. 2002; 277: 4936649373.
24. Quinn K, Tinker A. Protein kinase C and protein kinase A regulate Kir6.1/SUR2B but not Kir6.2/SUR2B in stably transfected HEK293 cells. Biophys J. 2002; 82: 201a. Abstract.
25. Thorneloe KS, Maruyama Y, Malcolm AT, Light PE, Walsh MP, Cole WC. Protein kinase C modulation of recombinant ATP-sensitive K+ channels composed of Kir6.1 and/or Kir6.2 expressed with SUR2B. J Physiol. 2002; 541: 6580.
26. Light PE, Sabir AA, Allen BG, Walsh MP, French RJ. Protein kinase Cinduced changes in the stoichiometry of ATP binding activate cardiac ATP-sensitive K+ channels: a possible mechanistic link to ischemic preconditioning. Circ Res. 1996; 79: 399406.
27. Hu K, Duan D, Li GR, Nattel S. Protein kinase C activates ATP-sensitive K+ current in human and rabbit ventricular myocytes. Circ Res. 1996; 78: 492498.
28. Cole WC, Malcolm T, Walsh MP, Light PE. Inhibition by protein kinase C of the KNDP subtype of vascular smooth muscle ATP-sensitive potassium channel. Circ Res. 2000; 87: 112117.
29. Hayabuchi Y, Davies NW, Standen NB. Angiotensin II inhibits rat arterial KATP channels by inhibiting steady-state protein kinase A activity and activating protein kinase C
. J Physiol. 2001; 530: 193205.
30. Haruna T, Yoshida H, Nakamura TY, Xie LH, Otani H, Ninomiya T, Takano M, Coetzee WA, Horie M.
1-Adrenoceptormediated breakdown of phosphatidylinositol 4,5-bisphosphate inhibits pinacidil-activated ATP-sensitive K+ currents in rat ventricular myocytes. Circ Res. 2002; 91: 232239.
31. Light PE, Allen BG, Walsh MP, French RJ. Regulation of adenosine triphosphate-sensitive potassium channels from rabbit ventricular myocytes by protein kinase C and type 2A protein phosphatase. Biochemistry. 1995; 34: 72527257.[CrossRef][Medline] [Order article via Infotrieve]
32. Light PE, Bladen C, Winkfein RJ, Walsh MP, French RJ. Molecular basis of protein kinase C-induced activation of ATP-sensitive potassium channels. Proc Natl Acad Sci U S A. 2000; 97: 90589063.
33. Jovanovic N, Jovanovic S, Jovanovic A, Terzic A. Gene delivery of Kir6.2/SUR2A in conjunction with pinacidil handles intracellular Ca2+ homeostasis under metabolic stress. FASEB J. 1999; 13: 923929.
34. Nasuhoglu C, Feng S, Mao Y, Shammat I, Yamamato M, Earnest S, Lemmon M, Hilgemann DW. Modulation of cardiac PIP2 by cardioactive hormones and other physiologically relevant interventions. Am J Physiol. 2002; 283: C223C234.
35. Liou HH, Zhou SS, Huang CL. Regulation of ROMK1 channel by protein kinase A via a phosphatidylinositol 4,5-bisphosphate-dependent mechanism. Proc Natl Acad Sci U S A. 1999; 96: 58205825.
36. Rohacs T, Chen J, Prestwich GD, Logothetis DE. Distinct specificities of inwardly rectifying K+ channels for phosphoinositides. J Biol Chem. 1999; 274: 3606536072.
37. Wang C, Wang K, Wang W, Cui Y, Fan Z. Compromised ATP binding as a mechanism of phosphoinositide modulation of ATP-sensitive K+ channels. FEBS Lett. 2002; 532: 177182.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
J. Jiao, V. Garg, B. Yang, T. S. Elton, and K. Hu Protein Kinase C-{epsilon} Induces Caveolin-Dependent Internalization of Vascular Adenosine 5'-Triphosphate-Sensitive K+ Channels Hypertension, September 1, 2008; 52(3): 499 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Vaithianathan, A. Bukiya, J. Liu, P. Liu, M. Asuncion-Chin, Z. Fan, and A. Dopico Direct Regulation of BK Channels by Phosphatidylinositol 4,5-Bisphosphate as a Novel Signaling Pathway J. Gen. Physiol., July 1, 2008; 132(1): 13 - 28. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. V. Quinn, P. Behe, and A. Tinker Monitoring changes in membrane phosphatidylinositol 4,5-bisphosphate in living cells using a domain from the transcription factor tubby J. Physiol., June 15, 2008; 586(12): 2855 - 2871. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Shi, N. Cui, W. Shi, and C. Jiang A Short Motif in Kir6.1 Consisting of Four Phosphorylation Repeats Underlies the Vascular KATP Channel Inhibition by Protein Kinase C J. Biol. Chem., February 1, 2008; 283(5): 2488 - 2494. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Shi, N. Cui, Y. Shi, X. Zhang, Y. Yang, and C. Jiang Arginine vasopressin inhibits Kir6.1/SUR2B channel and constricts the mesenteric artery via V1a receptor and protein kinase C Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R191 - R199. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Brown, A. Thomas, L. V. Dekker, A. Tinker, and J. L. Leaney PKC-{delta} sensitizes Kir3.1/3.2 channels to changes in membrane phospholipid levels after M3 receptor activation in HEK-293 cells Am J Physiol Cell Physiol, September 1, 2005; 289(3): C543 - C556. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kinoshita, T. Azma, K. Nakahata, H. Iranami, Y. Kimoto, M. Dojo, O. Yuge, and Y. Hatano Inhibitory Effect of High Concentration of Glucose on Relaxations to Activation of ATP-Sensitive K+ Channels in Human Omental Artery Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2290 - 2295. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. V. Quinn, J. P. Giblin, and A. Tinker Multisite Phosphorylation Mechanism for Protein Kinase A Activation of the Smooth Muscle ATP-Sensitive K+ Channel Circ. Res., May 28, 2004; 94(10): 1359 - 1366. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |